Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Adverse Events During ART and Implications for Treatment: Key Data From Summer 2021
  • CME
  • CE

Eric S. Daar, MD
Released: September 22, 2021


To conclude this discussion, it is important to continue investigating how HIV therapy—both initial and subsequent/switch therapy—influences important metabolic parameters and AEs in patients.

We know that many of our therapeutics have some effect on lipids and weight. In this module, we focused on weight, BMI, and markers of cardiometabolic health based on new data from IAS 2021. However, as emerging therapies become available, the relevant AEs we evaluate will depend on the specific drugs in the regimen. 

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings